EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR
Ukhyun Jo(Center for Cancer Research), Yeul Hong Kim(Seoul National University Bundang Hospital)
Cited by 58
Related Papers
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
|The Lancet Oncology|2020|190
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents
|Molecular Cancer Therapeutics|2021|110
A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer
|Cancer Chemotherapy and Pharmacology|2017|31
The Novel ATR Inhibitor M1774 Induces Replication Protein Overexpression and Broad Synergy with DNA-targeted Anticancer Drugs
|Molecular Cancer Therapeutics|2024|23